The combination of anti-DLL4 and gemcitabine had additive antitumor activity in pancreatic cancer xenograft models and delayed tumor recurrence after termination of gemcitabine treatment targeting DLL4 both in tumor and in stroma/vasculature [582]. The gene discussed is DLL4; the disease is neoplasm.